Univariate and multivariate analysis of 35 patients with available IPI scores
| Variable . | Group . | n . | Univariate analysis . | Multivariate analysis . | |||
|---|---|---|---|---|---|---|---|
| 2-y OS, % . | Median, y . | P . | HR, median (95% CI) . | P . | |||
| Age, y | <60 | 10 | 50 | 1.87 | .960 | ||
| ≥60 | 25 | 64 | 2.92 | ||||
| Ann Arbor stage | I, II | 17 | 72.5 | 3.78 | .536 | ||
| III, IV | 18 | 50 | 2.32 | ||||
| No. of extranodal lesions | 0, 1 | 23 | 71.9 | 3.78 | .140 | ||
| ≥2 | 12 | 38.9 | 1.06 | ||||
| LDH higher than upper limit | No | 20 | 69.1 | 3.78 | .123 | ||
| Yes | 15 | 48.7 | 1.32 | ||||
| Performance status | 0, 1 | 25 | 82.5 | NA | <.001 | ||
| ≥2 | 10 | 10 | 0.40 | ||||
| IPI | Low, Low-int | 20 | 82.9 | NA | .006 | 1.00 | .073 |
| High, High-int | 15 | 33.3 | 1.06 | 2.81 (0.91-8.68) | |||
| Sex | Female | 10 | 46.7 | 1.32 | .475 | ||
| Male | 25 | 65.9 | 3.78 | ||||
| Initial therapy | CHOP like | 26 | 48.7 | 1.87 | .043 | 1.00 | .485 |
| Others | 9 | 100.0 | NA | 0.55 (0.10-2.93) | |||
| B-cell signature | No | 20 | 43.3 | 1.15 | .028 | 5.52 (1.74-17.5) | .004 |
| Yes | 15 | 85.1 | NA | 1.00 | |||
| DC signature | No | 25 | 48.9 | 1.87 | .058 | 8.23 (2.06-32.1) | .003 |
| Yes | 10 | 88.9 | NA | 1.00 | |||
| Macrophage signature | No | 22 | 69 | 3.78 | .130 | ||
| Yes | 13 | 46.2 | 1.06 | ||||
| Mast signature | No | 24 | 51.2 | 2.84 | .376 | ||
| Yes | 11 | 80.8 | 3.78 | ||||
| Variable . | Group . | n . | Univariate analysis . | Multivariate analysis . | |||
|---|---|---|---|---|---|---|---|
| 2-y OS, % . | Median, y . | P . | HR, median (95% CI) . | P . | |||
| Age, y | <60 | 10 | 50 | 1.87 | .960 | ||
| ≥60 | 25 | 64 | 2.92 | ||||
| Ann Arbor stage | I, II | 17 | 72.5 | 3.78 | .536 | ||
| III, IV | 18 | 50 | 2.32 | ||||
| No. of extranodal lesions | 0, 1 | 23 | 71.9 | 3.78 | .140 | ||
| ≥2 | 12 | 38.9 | 1.06 | ||||
| LDH higher than upper limit | No | 20 | 69.1 | 3.78 | .123 | ||
| Yes | 15 | 48.7 | 1.32 | ||||
| Performance status | 0, 1 | 25 | 82.5 | NA | <.001 | ||
| ≥2 | 10 | 10 | 0.40 | ||||
| IPI | Low, Low-int | 20 | 82.9 | NA | .006 | 1.00 | .073 |
| High, High-int | 15 | 33.3 | 1.06 | 2.81 (0.91-8.68) | |||
| Sex | Female | 10 | 46.7 | 1.32 | .475 | ||
| Male | 25 | 65.9 | 3.78 | ||||
| Initial therapy | CHOP like | 26 | 48.7 | 1.87 | .043 | 1.00 | .485 |
| Others | 9 | 100.0 | NA | 0.55 (0.10-2.93) | |||
| B-cell signature | No | 20 | 43.3 | 1.15 | .028 | 5.52 (1.74-17.5) | .004 |
| Yes | 15 | 85.1 | NA | 1.00 | |||
| DC signature | No | 25 | 48.9 | 1.87 | .058 | 8.23 (2.06-32.1) | .003 |
| Yes | 10 | 88.9 | NA | 1.00 | |||
| Macrophage signature | No | 22 | 69 | 3.78 | .130 | ||
| Yes | 13 | 46.2 | 1.06 | ||||
| Mast signature | No | 24 | 51.2 | 2.84 | .376 | ||
| Yes | 11 | 80.8 | 3.78 | ||||
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CI, confidence interval; HR, hazard ratio; int, intermediate; NA, not applicable.